Troxacitabine activity in extramedullary myeloid leukemia

Yesid Alvarado, Hagop M. Kantarjian, Jorge E. Cortes, Efrosynl Apostolidou, Carol Bivins, Francis J. Giles

Research output: Contribution to journalArticle

Abstract

Troxacitabine is a novel L-enantiomer nucleoside analog with unique properties in terms of its structure, pharmacokinetics, intracellular transport, and susceptibility to mechanisms of resistance. Troxacitabine has significant activity in patients with refractory myeloid leukemias, both as a single agent and when combined with standard anti-leukemia agents. In a cohort of 170 patients with refractory myeloid leukemia treated with troxacitabine-based regimens on Phase 1 or 2 studies, 10 (6%) had biopsy-proven extramedullary disease, either with or without bone marrow involvement. Six of these patients who received single-agent troxacitabine, 4 received a combination of troxacitabine and cytarabine. Complete response and disappearance of all extramedullary lesions were observed in 6 (60%) of these 10 patients. Two of the 6 responding patients relapsed within 3 months, 2 patients had remissions of 8 and 9 months duration, respectively, 1 patient is in on-going remission at 3, and 1 patient is lost to follow-up. Troxacitabine-based therapy had significant antileukemic activity in extramedullary myeloid leukemias and warrants further investigation in this clinical situation.

Original languageEnglish (US)
Pages (from-to)179-185
Number of pages7
JournalHematology
Volume7
Issue number3
DOIs
StatePublished - Jan 1 2002
Externally publishedYes

Fingerprint

Myeloid Leukemia
troxacitabine
Lost to Follow-Up
Cytarabine
Nucleosides
Leukemia
Pharmacokinetics
Bone Marrow
Biopsy

Keywords

  • Cytarabine
  • Extramedullary
  • Myeloid leukemias
  • Troxacitabine

ASJC Scopus subject areas

  • Hematology

Cite this

Alvarado, Y., Kantarjian, H. M., Cortes, J. E., Apostolidou, E., Bivins, C., & Giles, F. J. (2002). Troxacitabine activity in extramedullary myeloid leukemia. Hematology, 7(3), 179-185. https://doi.org/10.1080/1024533021000008155

Troxacitabine activity in extramedullary myeloid leukemia. / Alvarado, Yesid; Kantarjian, Hagop M.; Cortes, Jorge E.; Apostolidou, Efrosynl; Bivins, Carol; Giles, Francis J.

In: Hematology, Vol. 7, No. 3, 01.01.2002, p. 179-185.

Research output: Contribution to journalArticle

Alvarado, Y, Kantarjian, HM, Cortes, JE, Apostolidou, E, Bivins, C & Giles, FJ 2002, 'Troxacitabine activity in extramedullary myeloid leukemia', Hematology, vol. 7, no. 3, pp. 179-185. https://doi.org/10.1080/1024533021000008155
Alvarado Y, Kantarjian HM, Cortes JE, Apostolidou E, Bivins C, Giles FJ. Troxacitabine activity in extramedullary myeloid leukemia. Hematology. 2002 Jan 1;7(3):179-185. https://doi.org/10.1080/1024533021000008155
Alvarado, Yesid ; Kantarjian, Hagop M. ; Cortes, Jorge E. ; Apostolidou, Efrosynl ; Bivins, Carol ; Giles, Francis J. / Troxacitabine activity in extramedullary myeloid leukemia. In: Hematology. 2002 ; Vol. 7, No. 3. pp. 179-185.
@article{ad362b6c114d4ace9654215e7b725a64,
title = "Troxacitabine activity in extramedullary myeloid leukemia",
abstract = "Troxacitabine is a novel L-enantiomer nucleoside analog with unique properties in terms of its structure, pharmacokinetics, intracellular transport, and susceptibility to mechanisms of resistance. Troxacitabine has significant activity in patients with refractory myeloid leukemias, both as a single agent and when combined with standard anti-leukemia agents. In a cohort of 170 patients with refractory myeloid leukemia treated with troxacitabine-based regimens on Phase 1 or 2 studies, 10 (6{\%}) had biopsy-proven extramedullary disease, either with or without bone marrow involvement. Six of these patients who received single-agent troxacitabine, 4 received a combination of troxacitabine and cytarabine. Complete response and disappearance of all extramedullary lesions were observed in 6 (60{\%}) of these 10 patients. Two of the 6 responding patients relapsed within 3 months, 2 patients had remissions of 8 and 9 months duration, respectively, 1 patient is in on-going remission at 3, and 1 patient is lost to follow-up. Troxacitabine-based therapy had significant antileukemic activity in extramedullary myeloid leukemias and warrants further investigation in this clinical situation.",
keywords = "Cytarabine, Extramedullary, Myeloid leukemias, Troxacitabine",
author = "Yesid Alvarado and Kantarjian, {Hagop M.} and Cortes, {Jorge E.} and Efrosynl Apostolidou and Carol Bivins and Giles, {Francis J.}",
year = "2002",
month = "1",
day = "1",
doi = "10.1080/1024533021000008155",
language = "English (US)",
volume = "7",
pages = "179--185",
journal = "Hematology",
issn = "1024-5340",
publisher = "Taylor and Francis Ltd.",
number = "3",

}

TY - JOUR

T1 - Troxacitabine activity in extramedullary myeloid leukemia

AU - Alvarado, Yesid

AU - Kantarjian, Hagop M.

AU - Cortes, Jorge E.

AU - Apostolidou, Efrosynl

AU - Bivins, Carol

AU - Giles, Francis J.

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Troxacitabine is a novel L-enantiomer nucleoside analog with unique properties in terms of its structure, pharmacokinetics, intracellular transport, and susceptibility to mechanisms of resistance. Troxacitabine has significant activity in patients with refractory myeloid leukemias, both as a single agent and when combined with standard anti-leukemia agents. In a cohort of 170 patients with refractory myeloid leukemia treated with troxacitabine-based regimens on Phase 1 or 2 studies, 10 (6%) had biopsy-proven extramedullary disease, either with or without bone marrow involvement. Six of these patients who received single-agent troxacitabine, 4 received a combination of troxacitabine and cytarabine. Complete response and disappearance of all extramedullary lesions were observed in 6 (60%) of these 10 patients. Two of the 6 responding patients relapsed within 3 months, 2 patients had remissions of 8 and 9 months duration, respectively, 1 patient is in on-going remission at 3, and 1 patient is lost to follow-up. Troxacitabine-based therapy had significant antileukemic activity in extramedullary myeloid leukemias and warrants further investigation in this clinical situation.

AB - Troxacitabine is a novel L-enantiomer nucleoside analog with unique properties in terms of its structure, pharmacokinetics, intracellular transport, and susceptibility to mechanisms of resistance. Troxacitabine has significant activity in patients with refractory myeloid leukemias, both as a single agent and when combined with standard anti-leukemia agents. In a cohort of 170 patients with refractory myeloid leukemia treated with troxacitabine-based regimens on Phase 1 or 2 studies, 10 (6%) had biopsy-proven extramedullary disease, either with or without bone marrow involvement. Six of these patients who received single-agent troxacitabine, 4 received a combination of troxacitabine and cytarabine. Complete response and disappearance of all extramedullary lesions were observed in 6 (60%) of these 10 patients. Two of the 6 responding patients relapsed within 3 months, 2 patients had remissions of 8 and 9 months duration, respectively, 1 patient is in on-going remission at 3, and 1 patient is lost to follow-up. Troxacitabine-based therapy had significant antileukemic activity in extramedullary myeloid leukemias and warrants further investigation in this clinical situation.

KW - Cytarabine

KW - Extramedullary

KW - Myeloid leukemias

KW - Troxacitabine

UR - http://www.scopus.com/inward/record.url?scp=0036402413&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036402413&partnerID=8YFLogxK

U2 - 10.1080/1024533021000008155

DO - 10.1080/1024533021000008155

M3 - Article

C2 - 12243982

AN - SCOPUS:0036402413

VL - 7

SP - 179

EP - 185

JO - Hematology

JF - Hematology

SN - 1024-5340

IS - 3

ER -